360 Results for "

chimeric

" in MedChemExpress (MCE) Product Catalog:
Products (360)

360 Results for "chimeric" in MCE Product Catalog:

58
58 Publications Verification
Cat. No.: HY-P9905
CAS No.: 205923-56-4
Synonyms: C225; IMC-C225
Research Areas:  

Cancer

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-P9970
CAS No.: 170277-31-3
Synonyms: Avakine; CT-P13; SB2; TA-650
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-P9970A
Synonyms: Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-P9913
CAS No.: 174722-31-7
Synonyms: Anti-Human CD20 type I, chimeric Antibody; HSDB 7455; IDEC-C2B8
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-P9913A
CAS No.: 174722-31-7
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P99029
CAS No.: 2169232-81-7
Synonyms: Hu5F9-G4

Target:  

CD47

Research Areas:  

Cancer

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-153321
CAS No.: 2649400-34-8
Purity:  98.67%
Synonyms: NX-5948; BTK-IN-24
Target:  

PROTACs Btk

Research Areas:  

Inflammation/Immunology

Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99058
CAS No.: 1496553-00-4
Synonyms: IMAB362; Claudiximab; GC-182

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9956
CAS No.: 541502-14-1
Synonyms: CNTO-328

Target:  

Interleukin Related

Research Areas:  

Cancer

Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99151
CAS No.: 2088770-90-3
Synonyms: CAC-10

Research Areas:  

Cancer

Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99006
CAS No.: 931402-35-6
Synonyms: MORab-009

Target:  

Mesothelin

Research Areas:  

Cancer

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153342
CAS No.: 2750830-09-0
Purity:  98.99%
Synonyms: ARV-766; JSB462
Research Areas:  

Cancer

Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-17573
CAS No.: 37025-55-1
Target:  

Oxytocin Receptor

Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-17573A
CAS No.: 1631754-28-3
Target:  

Oxytocin Receptor

Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99225
CAS No.: 1453084-36-0
Synonyms: M9346A

Research Areas:  

Cancer

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99407
CAS No.: 2097151-87-4
Synonyms: VX 15/2503

Target:  

Inhibitory Antibodies

Research Areas:  

Neurological Disease Cancer

Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99575
CAS No.: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Research Areas:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99333
CAS No.: 558480-40-3
Synonyms: M200; Eos 200-4

Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9934
CAS No.: 143653-53-6
Synonyms: C7E3

Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99008
CAS No.: 2417175-94-9
Synonyms: IC14
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
loading...
    loading...